The research group Neugut specialized in Pathophysiology and Pharmacology Gastrointestinal Tract and directed by Dr.. Abalo, has made significant contributions to the understanding of the effects produced by the use of cannabinoids in the gastrointestinal tract, particularly those related to the motility. Dr. Abalo has recently participated in the World Congress of Gastroenterology in Istanbul (Turkey) and the Congress of the Polish Society of Pathology (Lublin, Poland) to expose the main results of their studies.

In his talk presented in Istanbul on Monday 23 September, showed how cannabis and cannabinoids may be useful as anti-emetics for nausea and as antidiarrheal, not only to deal with the dreaded side effects of chemotherapy, but also in stubborn cases of nausea and vomiting after bariatric surgery or diarrhea from other etiologies. Furthermore, the researcher URJC noted that "use, particularly when prolonged and high doses are used, may be associated not only adverse effects on the mental sphere, including addiction or the appearance of psychosis, but also toxicity gastrointestinal".

In the context of progressive legalization of medicinal and recreational use of cannabis in many countries, Dr. Abalo warned of the need for well-designed studies to establish therapeutic indications, routes and most beneficial dose for patients, adding that " any case, this use must be responsible and cautious, not indiscriminate, for the possible occurrence of central and peripheral adverse effects. "

In his second intervention, under the Congress of the Polish Society of Pathology, held last Friday, 27 September, Dr. Abalo showed the Polish Pathologists the advantages of using special preparations "broadsheet" that, according to the researcher, "allow a massive count of neurons residing in the gastrointestinal tract motility and control, differentiating their distinct subpopulations according to their electrophysiological, morphological, immunohistochemical and functional characteristics". By using these techniques, the Neugut group was the first to describe enteric neuropathy (disease affecting the bowel neurons) associated with administration of various chemotherapeutic treatment cycles in preclinical models.

Some of these results were also obtained in collaboration with the group of Dr. Nurgali (Victoria University, Melbourne, Australia), with which also Dr. Abalo recently co - edited a special issue on Frontiers in Pharmacology and Frontiers in Oncology on the adverse effects associated with cancer chemotherapy. Both groups are world leaders in the study, in preclinical models, the effects of cancer chemotherapy on the functions of the nervous system in the gastrointestinal tract as well as possible preventive and therapeutic strategies. Their results are intended to help preserve the quality of life of cancer patients, which show an increasing survival.

Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream